Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial
Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial
复制标题
DOI：
10.2217/rme-2018-0161
复制
发表时间：
2019-03-01
影响因子：
2.7
通讯作者：
Boyd, Richard
中科院分区：
文献类型：
--
作者：
Freitag, Julien;Bates, Dan;Boyd, Richard
目的：评价自体脂肪间充质干细胞（ADMSC）治疗膝骨关节炎的疼痛、功能和疾病改善的疗效。方法：将30例有症状的膝关节骨性关节炎患者随机分为三组。两个治疗组接受关节内ADMSC治疗，包括单次注射（100 x 106个ADMSC）或两次注射（基线和6个月时100 x 106个ADMSC）。第三组作为对照组，继续保守管理。结果：未观察到严重不良事件。接受ADMSC的两个治疗组在12个月完成随访时均表现出临床显着的疼痛和功能改善。使用磁共振成像骨关节炎膝关节评分进行的放射学分析表明疾病进展有所改善。结论：自体ADMSC治疗似乎是膝关节骨关节炎的一种安全有效的治疗方法，并有可能预防疾病进展。
Aim: To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis. Methods: 30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 x 10(6) ADMSCs) or two injections (100 x 10(6) ADMSCs at baseline and 6 months). The third group served as control and continued conservative management. Results: No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression. Conclusion: Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.